<DOC>
	<DOCNO>NCT02303821</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ass safety , tolerability activity carfilzomib , alone combination induction chemotherapy , child relapse refractory acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>Study Carfilzomib Combination With Induction Chemotherapy Children With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key 1 . Age 21 year young time initial ALL diagnosis age &gt; 1 year time study treatment initiation . 2 . Subjects must diagnosis relapsed refractory ALL ≥ 5 % blast bone marrow ( M2 M3 disease ) , without extramedullary disease . To eligible , subject must 1 prior therapeutic attempt , define : Early first relapse ( &lt; 36 month original diagnosis ) achieve CR ( BALL ) first relapse time follow original diagnosis achieve CR ( TALL ) Relapse achieve CR follow first subsequent relapse ( i.e. , ≥ 2 relapse ) OR Failing achieve CR original diagnosis least 1 induction attempt 3 . Subjects must fully recover acute toxic effect previous chemotherapy , immunotherapy , radiotherapy treatment enrollment . 4 . Subjects must serum creatinine level ≤ 1.5 × institutional upper limit normal ( ULN ) accord age . If serum creatinine level &gt; 1.5 × ULN , subject must calculate creatinine clearance radioisotope glomerular filtration rate ( GFR ) ≥ 70 mL/min/1.73 m2 . 5 . Adequate liver function , define follow : Total bilirubin ≤ 1.5 × institutional ULN except presence Gilbert Syndrome Alanine aminotransferase ( ALT ) ≤ 5 × institutional ULN 6 . Performance status : Karnofsky Lansky score ≥ 50 subject &gt; 16 year old ≤ 16 year old , respectively . Key 1 . Known allergy drug use study . ( Subjects previous allergy PEGasparaginase receive Erwinia eligible . ) 2 . Known allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) 3 . Left ventricular fractional shortening &lt; 30 % 4 . History ≥ Grade 2 pancreatitis 5 . Active graft‑versus‑host disease require systemic treatment 6 . Positive culture clinical evidence infection bacteria fungus within 14 day initiation study treatment 7 . Down Syndrome 8 . Prior therapy restriction : Subjects must complete therapy granulocyte‑colony stimulate factor ( G‑CSF ) myeloid growth factor least 7 day study treatment initiation , least 14 day study treatment initiation , pegylated myeloid growth factor administer . Subjects must complete type active immunotherapy ( e.g. , tumor vaccine ) least 42 day study treatment initiation . At least 3 antibody half‑lives must elapse since last dose monoclonal antibody ( e.g. , 66 day rituximab 69 day epratuzumab ) subject may initiate study treatment . Subjects must complete type active immunotherapy ( e.g. , tumor vaccine ) least 42 day study treatment initiation . Subjects must receive antineoplastic agent therapeutic intent , exclude hydroxyurea antimetabolite administer part maintenance chemotherapy , within 7 day prior study treatment initiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>